Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The year has not been kind to cannabis producer Sundial Growers (NASDAQ: SNDL ). After an amazing but volatile 2020, SNDL stock is down 25% in the last month. Source: Shutterstock It seems the Reddit-induced r...
Radius Health (RDUS) reported that patient growth for its osteoporosis drug Tymlos (abaloparatide) increased 14% in Q1 compared to Q4 2020.The company also said it completed a pharmacokinetic study comparing a patch version of Tymlos to the injectable version.Radius added the company is on tr...
Growth of 14% for new U.S. TYMLOS® patients in Q1, 2021 vs. Q4, 2020 Q1, 2021 TYMLOS net revenue impacted by seasonality and distribution channel destocking April, 2021 month-to-date new patient adds indicate significant patient growth Three pivotal studies: all remain ...
BOSTON, April 20, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide...
RDUS has an approved drug that generates over $200mn in revenue. It has multiple label expansion prospects for this drug. However, the stock stays depressed because the late-stage pipeline isn't diverse enough. For further details see: Radius Health: Commercial Stage Com...
Radius Health ([[RDUS]] -5.9%) announced that its partner Teijin Pharma has received regulatory approval in Japan for Ostabaro in the treatment of osteoporosis and promotion of bone formation in patients with a high risk of fractures.The approval is expected to generate $10M in mile...
Regulatory success achieved in Japan by partner Teijin Pharma Limited Ostabaro® approved for treatment of male & female OP patients at high risk of fracture Japan is currently the largest anabolic market in the world $10 million milestone to be generated from Japan ...
Radius Health ([[RDUS]] +14.3%) has reversed premarket losses to surge after Goldman Sachs assumed its coverage with a buy rating and a 12-month price target of $33.00 per share to imply ~46.8% upside to the previous close. The thesis is backed by consensus beating Tymlos reven...
Editas Medicine (EDIT) is trading ~3.8% higher in pre-market hours after Credit Suisse initiated coverage with an outperform rating. The price target of $58.00 per share indicates an upside of ~28.9% to the previous close.Analyst Tiago Fauth argues that the company is a pioneer in CRISPR...
Radius Health (RDUS) amends credit facilities of $175M, consisting of a $150M term loan, which includes a cashless conversion of $25M in existing term loans, and a $25M revolving credit facility.Company repurchases $112.2M of principal amount of the 3.00% convertible notes due September ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 54.4% to $0.4264 on volume of 158,036,142 shares Versus Systems Inc. (VS) rose 73.5% to $2.29 on volume of 40,036,424 shares Tesla Inc. (TSLA) rose 5.3% to $220.97 on volume of 32,375,487 shar...
Ferrous, Nonferrous and Finished Steel Sales Volumes Up Sequentially Radius Board Declares Quarterly Dividend PORTLAND, Ore., July 02, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ: RDUS) today reported results for the third quarter of fiscal 2024 ended May 31, 2024. ...